Physician profile
Ralph Ortiz
NPI 1720171879
$5,735.37
in general payments reported to CMS, 2019-2025
28 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $1,264 · 2021: $1,287 · 2022: $632 · 2023: $515 · 2024: $403 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,231.02 | 2019-2023 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $817.74 | 2020-2025 | Relistor |
| Si-Bone, INC. | $459.00 | 2020-2022 | |
| Spr Therapeutics, INC | $388.23 | 2023-2025 | Sprint Pns System |
| Abbvie INC. | $340.48 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $336.83 | 2020-2021 | |
| Pfizer INC. | $315.49 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $163.29 | 2025 | |
| Daiichi Sankyo INC. | $152.19 | 2019 | |
| Scilex Pharmaceuticals INC. | $128.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2020 | |
| Protega Pharmaceutials INC | $112.02 | 2025 | Roxybond |
| Regeneron Healthcare Solutions, INC. | $110.00 | 2020 | |
| Merck Sharp & Dohme LLC | $109.60 | 2019 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sentynl Therapeutics, INC. | $97.80 | 2019 | |
| Nevro Corp. | $97.00 | 2019 | |
| Biodelivery Sciences International, INC. | $96.43 | 2021 | |
| Genzyme Corporation | $95.31 | 2022 | |
| Assertio Therapeutics, INC. | $82.61 | 2019-2020 | |
| Medtronic, INC. | $80.05 | 2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $69.31 | 2020 | |
| Virtus Pharmaceuticals LLC | $59.54 | 2021 | |
| Zyla Life Sciences, INC. | $58.35 | 2020 | |
| Hydrocision, INC. | $49.24 | 2023 | Tenjet |
| Grt US Holding, INC. | $28.90 | 2022 | |
| Averitas Pharma INC. | $20.66 | 2025 | Qutenza |
| Foundation Fusion Solutions, LLC | $12.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.